Genetic Polymorphism of Drug Metabolising Enzymes in African Populations: Implications for the Use of Neuroleptics and Antidepressants

This publication has 62 references indexed in Scilit:

• A novel mutant variant of the CYP2D6 gene (CYP2D617) common in a black African population: association with diminished debrisoquine hydroxylase activity
  British Journal of Clinical Pharmacology, 1996
• Lack of effect of chloroquine on the debrisoquine (CYP2D6) and S‐mephenytoin (CYP2C19) hydroxylation phenotypes
  British Journal of Clinical Pharmacology, 1996
• Fluvoxamine and fluoxetine: interaction studies with amitriptyline, clomipramine and neuroleptics in phenotyped patients
  Pharmacological Research, 1995
• Genetic polymorphism of cytochrome P450 CYP2D6 in Zimbabwean population
  Pharmacogenetics, 1993
• Evidence for a new variant CYP2D6 allele CYP2D6J in a Japanese population associated with lower in vivo rates of sparteine metabolism
  Pharmacogenetics, 1993
• Evidence for a dissociation in the control of sparteine, debrisoquine and metoprolol metabolism in Nigerians
  Pharmacogenetics, 1992
• Identification of a new variant CYP2D6 allele lacking the codon encoding Lys-281: possible association with the poor metabolizer phenotype
  Pharmacogenetics, 1991
• Ethnic Differences in Drug Disposition and Responsiveness
  Clinical Pharmacokinetics, 1991
• Genetic Polymorphism of Sparteine/Debrisoquine Oxidation: A Reappraisal
  Basic & Clinical Pharmacology & Toxicology, 1990
• Recent Developments in Hepatic Drug Oxidation
  Clinical Pharmacokinetics, 1990